Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 16:30 UTC |
Coll Crespo BlasCHIEF MEDICAL OFFICER
|
GrantOrdinary Shares | 75,897 | $0.00 | $0.00 |
DisclosureSEC source: 0002037144-26-000003 · form4-03232026_040308.xml · nonDerivative · entry 1 Coll Crespo Blas · CIK 0002037144 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,878 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 16:30 UTC |
Hall AshleyChief Development Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 59,073 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001801842-26-000003 · form4-03232026_040310.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,073 Underlying: Ordinary Shares · 59,073 shares Expires 2036-03-18 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 16:30 UTC |
Hall AshleyChief Development Officer
|
GrantOrdinary Shares | 47,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001801842-26-000003 · form4-03232026_040310.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,187 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Stevens Raymond CDirector · CHIEF EXECUTIVE OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 322,230 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001698149-26-000003 · form4-03232026_040301.xml · derivative · entry 3 Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,230 Underlying: Ordinary Shares · 322,230 shares Expires 2036-03-18 F4 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Stevens Raymond CDirector · CHIEF EXECUTIVE OFFICER
|
GrantOrdinary Shares | 260,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001698149-26-000003 · form4-03232026_040301.xml · nonDerivative · entry 1 Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,401,593 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Ma YingliCHIEF TECHNOLOGY OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 40,278 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001963664-26-000003 · form4-03232026_040307.xml · derivative · entry 2 Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,278 Underlying: Ordinary Shares · 40,278 shares Expires 2036-03-18 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Ma YingliCHIEF TECHNOLOGY OFFICER
|
GrantOrdinary Shares | 32,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001963664-26-000003 · form4-03232026_040307.xml · nonDerivative · entry 1 Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,917 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Lin XichenCHIEF SCIENTIFIC OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 53,703 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001962926-26-000003 · form4-03232026_040305.xml · derivative · entry 2 Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,703 Underlying: Ordinary Shares · 53,703 shares Expires 2036-03-18 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Lin XichenCHIEF SCIENTIFIC OFFICER
|
GrantOrdinary Shares | 43,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001962926-26-000003 · form4-03232026_040305.xml · nonDerivative · entry 1 Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,960 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Yoon JunCHIEF FINANCIAL OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 128,892 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001962414-26-000003 · form4-03232026_040303.xml · derivative · entry 3 Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,892 Underlying: Ordinary Shares · 128,892 shares Expires 2036-03-18 F4 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F5 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 20:30 UTC |
Yoon JunCHIEF FINANCIAL OFFICER
|
GrantOrdinary Shares | 104,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001962414-26-000003 · form4-03232026_040303.xml · nonDerivative · entry 1 Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,401,656 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 18:20 UTC |
Coll Crespo BlasCHIEF MEDICAL OFFICER
|
Tax withholdingOrdinary Shares | 11,826 | $20.99 | $248,227.74 |
DisclosureSEC source: 0002037144-26-000002 · form4-03052026_060312.xml · nonDerivative · entry 1 Coll Crespo Blas · CIK 0002037144 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,981 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 18:20 UTC |
Hall AshleyChief Development Officer
|
Tax withholdingOrdinary Shares | 4,836 | $20.99 | $101,507.64 |
DisclosureSEC source: 0001801842-26-000002 · form4-03052026_060304.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,481 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:20 UTC |
Stevens Raymond CDirector · CHIEF EXECUTIVE OFFICER
|
Tax withholdingOrdinary Shares | 53,454 | $20.99 | $1,121,999.46 |
DisclosureSEC source: 0001698149-26-000002 · form4-03052026_060301.xml · nonDerivative · entry 1 Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,141,376 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:20 UTC |
Ma YingliCHIEF TECHNOLOGY OFFICER
|
Tax withholdingOrdinary Shares | 11,313 | $20.99 | $237,459.87 |
DisclosureSEC source: 0001963664-26-000002 · form4-03052026_060310.xml · nonDerivative · entry 1 Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,391 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:20 UTC |
Lin XichenCHIEF SCIENTIFIC OFFICER
|
Tax withholdingOrdinary Shares | 18,735 | $20.99 | $393,247.65 |
DisclosureSEC source: 0001962926-26-000002 · form4-03052026_060307.xml · nonDerivative · entry 1 Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,592 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:20 UTC |
Yoon JunCHIEF FINANCIAL OFFICER
|
Tax withholdingOrdinary Shares | 22,305 | $20.99 | $468,181.95 |
DisclosureSEC source: 0001962414-26-000002 · form4-03052026_060306.xml · nonDerivative · entry 1 Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,297,571 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 230 | $85.04 | $19,559.20 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 11 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 48,256 Underlying: Ordinary Shares · 690 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F5 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 6,498 | $84.22 | $547,261.56 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 10 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 48,486 Underlying: Ordinary Shares · 19,494 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F4 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 3,880 | $83.35 | $323,398.00 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 9 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 54,984 Underlying: Ordinary Shares · 11,640 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 5,477 | $82.10 | $449,661.70 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 8 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP LP Disclosed balance after: 58,864 Underlying: Ordinary Shares · 16,431 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 20 | $85.04 | $1,700.80 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 7 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 4,103 Underlying: Ordinary Shares · 60 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F5 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 552 | $84.22 | $46,489.44 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 6 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 4,123 Underlying: Ordinary Shares · 1,656 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F4 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 330 | $83.35 | $27,505.50 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 5 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 4,675 Underlying: Ordinary Shares · 990 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 14:22 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 465 | $82.10 | $38,176.50 |
DisclosureSEC source: 0001193125-26-016062 · ownership.xml · derivative · entry 4 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 5,005 Underlying: Ordinary Shares · 1,395 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information F1 · derivative.exercise_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F1 · derivative.expiration_date: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 15,535 | $61.45 | $954,625.75 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 13 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 0 Underlying: Ordinary Shares · 46,605 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F6 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 16,635 | $61.05 | $1,015,566.75 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 12 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 15,535 Underlying: Ordinary Shares · 49,905 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F5 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 5,589 | $94.61 | $528,775.29 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 11 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 32,170 Underlying: Ordinary Shares · 16,767 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F4 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 2,159 | $94.00 | $202,946.00 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 10 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 37,759 Underlying: Ordinary Shares · 6,477 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 8,337 | $92.52 | $771,339.24 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 9 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP Disclosed balance after: 39,918 Underlying: Ordinary Shares · 25,011 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 1,320 | $61.45 | $81,114.00 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 8 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 1 Underlying: Ordinary Shares · 3,960 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F6 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 1,414 | $61.05 | $86,324.70 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 7 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 1,321 Underlying: Ordinary Shares · 4,242 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F5 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 475 | $94.61 | $44,939.75 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 6 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 2,735 Underlying: Ordinary Shares · 1,425 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F4 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 183 | $94.00 | $17,202.00 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 5 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 3,210 Underlying: Ordinary Shares · 549 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 19:07 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 709 | $92.52 | $65,596.68 |
DisclosureSEC source: 0001193125-25-313977 · ownership.xml · derivative · entry 4 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP Disclosed balance after: 3,393 Underlying: Ordinary Shares · 2,127 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| November 20, 2025 Filed Mar 5, 2026 18:20 UTC |
Hall AshleyChief Development Officer
|
GrantAmerican Depositary Shares · Derivative | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001801842-26-000002 · form4-03052026_060304.xml · derivative · entry 3 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462 Underlying: Ordinary Shares · 711 shares Expires not disclosed F3 · derivative.exercise_price: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F5 · kind: Voluntary reporting of the acquisition of 237 ADSs by the Reporting Person on November 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan. F3 · derivative.exercise_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F3 · derivative.expiration_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| November 20, 2025 Filed Mar 5, 2026 23:20 UTC |
Stevens Raymond CDirector · CHIEF EXECUTIVE OFFICER
|
GrantAmerican Depositary Shares · Derivative | 824 | $0.00 | $0.00 |
DisclosureSEC source: 0001698149-26-000002 · form4-03052026_060301.xml · derivative · entry 3 Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,824 Underlying: Ordinary Shares · 2,472 shares Expires not disclosed F4 · derivative.exercise_price: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F5 · kind: Voluntary reporting of the acquisition of 824 ADSs by the Reporting Person on November 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan. F4 · derivative.exercise_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F4 · derivative.expiration_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 21:25 UTC |
Coll Crespo BlasCHIEF MEDICAL OFFICER
|
Tax withholdingOrdinary Shares | 8,106 | $7.74 | $62,767.19 |
DisclosureSEC source: 0002037144-25-000003 · form4-09222025_090901.xml · nonDerivative · entry 1 Coll Crespo Blas · CIK 0002037144 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,807 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 21:25 UTC |
Hall AshleyChief Development Officer
|
Tax withholdingOrdinary Shares | 6,021 | $7.74 | $46,622.41 |
DisclosureSEC source: 0001801842-25-000004 · form4-09222025_090903.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,317 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| July 30, 2025 Filed Aug 1, 2025 13:34 UTC |
FMR LLC10% owner · See Remark 1
|
SaleAmerican Depositary Shares · Derivative | 26,310 | $17.87 | $470,159.70 |
DisclosureSEC source: 0000950170-25-101141 · ownership.xml · derivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned Disclosed balance after: 1,515,558 Underlying: Ordinary Shares · 78,930 shares Expires not disclosed F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 17:15 UTC |
Coll Crespo BlasCHIEF MEDICAL OFFICER
|
Tax withholdingOrdinary Shares | 1,434 | $6.84 | $9,803.68 |
DisclosureSEC source: 0001415889-25-019354 · form4-07032025_050709.xml · nonDerivative · entry 3 Coll Crespo Blas · CIK 0002037144 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,913 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 17:15 UTC |
Coll Crespo BlasCHIEF MEDICAL OFFICER
|
GrantOrdinary Shares | 7,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019354 · form4-07032025_050709.xml · nonDerivative · entry 2 Coll Crespo Blas · CIK 0002037144 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,347 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F3 · kind: On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:15 UTC |
Stevens Raymond CDirector · CHIEF EXECUTIVE OFFICER
|
Tax withholdingOrdinary Shares | 16,050 | $6.84 | $109,727.43 |
DisclosureSEC source: 0001415889-25-019350 · form4-07032025_050702.xml · nonDerivative · entry 3 Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,194,830 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:15 UTC |
Stevens Raymond CDirector · CHIEF EXECUTIVE OFFICER
|
GrantOrdinary Shares | 89,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019350 · form4-07032025_050702.xml · nonDerivative · entry 2 Stevens Raymond C · CIK 0001698149 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,210,880 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F3 · kind: On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:15 UTC |
Ma YingliCHIEF TECHNOLOGY OFFICER
|
GrantOrdinary Shares | 24,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019353 · form4-07032025_050708.xml · nonDerivative · entry 2 Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,174 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F3 · kind: On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:15 UTC |
Lin XichenCHIEF SCIENTIFIC OFFICER
|
GrantOrdinary Shares | 57,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019352 · form4-07032025_050706.xml · nonDerivative · entry 2 Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,173 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F3 · kind: On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:15 UTC |
Yoon JunCHIEF FINANCIAL OFFICER
|
Tax withholdingOrdinary Shares | 7,089 | $6.84 | $48,464.66 |
DisclosureSEC source: 0001415889-25-019351 · form4-07032025_050704.xml · nonDerivative · entry 3 Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,319,876 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:15 UTC |
Yoon JunCHIEF FINANCIAL OFFICER
|
GrantOrdinary Shares | 39,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019351 · form4-07032025_050704.xml · nonDerivative · entry 2 Yoon Jun · CIK 0001962414 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,326,965 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F3 · kind: On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. Read SEC document |
| July 01, 2025 Filed Aug 20, 2025 21:00 UTC |
Ma YingliCHIEF TECHNOLOGY OFFICER
|
Tax withholdingOrdinary Shares | 4,470 | $6.84 | $30,559.60 |
DisclosureSEC source: 0001415889-25-022472 · form4-08202025_050803.xml · nonDerivative · entry 1 Ma Yingli · CIK 0001963664 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,704 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| July 01, 2025 Filed Aug 20, 2025 21:00 UTC |
Lin XichenCHIEF SCIENTIFIC OFFICER
|
Tax withholdingOrdinary Shares | 12,846 | $6.84 | $87,822.96 |
DisclosureSEC source: 0001415889-25-022471 · form4-08202025_050801.xml · nonDerivative · entry 1 Lin Xichen · CIK 0001962926 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,327 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.